This mechanism may justify the different susceptibilities of patients to cisplatin-induced AKI as nephrotoxicity that could be related to the abundance of renal progenitors, which is highly variable among different patients—differing by age, sex, and habits—and may open new therapeutic strategies or allow the use of tARPC released-CYP1B1 as potential predictor of nephrotoxicity risk in the future. Here, CYP1B1 is linked to acute kidney injury.